A study from the Austrian Breast & Colorectal Cancer Study Group indicates that women with metastasized breast cancer do not benefit from surgery performed prior to drug treatment. This could cause a paradigm shift in treatment of the disease.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
